Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Post-market, Randomized, Controlled, Prospective Study Evaluating Intrathecal Pain Medication (IT) Versus Conventional Medical Management (CMM) in the Non-cancer, Refractory, Chronic Pain Population (Prosper-001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04096391
Recruitment Status : Recruiting
First Posted : September 19, 2019
Last Update Posted : June 9, 2020
Sponsor:
Collaborators:
Flowonix Medical
Celéri Health
Advanced Infusion Solutions
Information provided by (Responsible Party):
Evolve Restorative Center

Brief Summary:
This study is being conducted to compare intrathecal morphine using the commercially available intrathecal drug delivery systems (IDDS), and conventional medical management (CMM) in subjects with non-cancer, refractory chronic pain.

Condition or disease Intervention/treatment Phase
Chronic Nonmalignant Pain Pain, Intractable Pain, Chronic Device: Flowonix Prometra® II Programmable Infusion System Drug: Pain Medicine Not Applicable

Detailed Description:

This study will evaluate the following objectives:

Primary objective:

1. To compare the change in pain intensity from baseline based on the Numeric Rating Scale [NRS] between subjects randomized to the IDDS group and subjects randomized to the CMM group.The comparison will be conducted at 3, 6, 9 and 12 months following enrollment. The evaluation at 6 months will be considered the primary time point for evaluation.

Secondary objectives:

For each of the following secondary objectives, the comparisons between the IDDS group and CMM group will be made using the intra-subject change from baseline as the dependent variable.

  1. Compare the subject reported PROMIS 29 between the IDDS group and CMM group. Individual subject scores recorded at baseline and months 3, 6, 9 and 12.
  2. Compare the accrued cost of therapy for pain control including those related to adverse events, ED visits, cost of medications between the IDDS group and CMM group
  3. Compare the number of other concurrent treatments performed on each subject between the IDDS group and CMM group. Individual subject counts recorded at months 3, 6, 9 and 12 will be compared.

Additional safety objective:

1. To characterize pain and device related adverse events for all subjects throughout the study through completion of 12 month follow-up or subject exit.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 82 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Subjects will be randomized in a 1:1 ratio to one of two groups
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Post-market, Randomized, Controlled, Prospective Study Evaluating Intrathecal Pain Medication (IT) Versus Conventional Medical Management (CMM) in the Non-cancer, Refractory, Chronic Pain Population (PROSPER)
Actual Study Start Date : June 5, 2019
Estimated Primary Completion Date : January 31, 2022
Estimated Study Completion Date : July 31, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Chronic Pain

Arm Intervention/treatment
Active Comparator: Intrathecal Drug Delivery System
Subjects randomized to the Intrathecal Drug Delivery System group will be implanted with the Prometra System under sterile technique in accordance with the Instructions for Use. The pump will be filled at the time of implantation with the prescribed medication.
Device: Flowonix Prometra® II Programmable Infusion System
The Flowonix Prometra® II Programmable Infusion System consists of an implanted infusion pump and catheter, and external components including a clinician programmer, refill and catheter access port kits, the PTC™(a subject operated controller).

Active Comparator: Conventional Medical Management
Subjects randomized to the Conventional Medical Management group will continue with the standard of care procedures.
Drug: Pain Medicine
Injections, spinal cord stimulation, peripheral nerve stimulation, pain medication, etc.
Other Name: Systemic opioid therapy




Primary Outcome Measures :
  1. Compare the change in Numeric Pain Rating Scale between the IDDS group and the CMM group [ Time Frame: Comparisons will be done prior to baseline visit and at 3, 6, 9 and 12 month visits. ]

    The Numeric Pain Rating Scale (NPRS) is a 0-10 numeric pain rating scale (11 point scale), where a higher scores equates to more pain.

    The primary endpoint for this post-marketing study is the comparison of the NPRS between the IDDS group and the CMM group collected in the Study Diary at various time points.



Secondary Outcome Measures :
  1. Compare the change in PROMIS 29 scores between the IDDS group and CMM group [ Time Frame: Individual subject scores recorded at baseline visit and at 3, 6, 9 and 12 month visits. ]
    Compare the subject reported Patient-Reported Outcomes Measurement Information System (PROMIS) 29 between the IDDS group and CMM group. PROMIS 29 assesses pain intensity using a 0-10 numeric rating scale (11 point scale), where a higher score equates to more pain. Other health domains are scored using a Likert scale, where higher scores represent more of the specific domain being measured. The other health domains that are scored are: depression; anxiety; physical function; pain interference; fatigue; sleep disturbance; and ability to participate in social roles and activities.

  2. Comparison of the accrued cost of therapy for pain [ Time Frame: Cost of therapy will be obtained at 3, 6, 9 and 12 month visits. ]
    Compare the accrued cost of therapy for pain control including those related to adverse events, ED visits, cost of medications between the IDDS group and CMM group.

  3. Comparison of other concurrent treatments [ Time Frame: Individual subject counts recorded at 3, 6, 9 and 12 month visits will be compared. ]
    Compare the number of other concurrent treatments performed on each subject between the IDDS group and CMM group.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   22 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject must have signed and dated the IRB approved Informed Consent Form and HIPAA Authorization prior to any study procedures being performed
  2. Subject must be willing and able to complete study requirements including diaries, questionnaires and attend all visits, in the opinion of the investigator
  3. Subject must be male or female and at least 22 years of age
  4. Subjects who are female are non-lactating and if of childbearing potential have a negative urine pregnancy test at screening
  5. Subjects who are currently be receiving ≤ 90 mg/day morphine per day dose (or MME), with stable dose at equivalent of systemic opioids at Screening
  6. Subjects who are on a stable dose of opioids (no change in type or prescribed frequency or dose) for 30 days prior to the screening as documented in medical history;
  7. Subjects who have refractory pain despite failure of regional minimally invasive treatment options, including epidurals, facets, rhizotomies, direct or indirect spinal stenosis treatments, etc.
  8. Subjects who are a new candidate for chronic intrathecal drug therapy (including no prior intrathecal/epidural trial for pump infusion therapy)
  9. Subjects have not been implanted with a spinal cord stimulator for pain
  10. Subjects currently do not have an implanted spinal cord stimulator for pain
  11. Subjects who have a diagnosis of nonmalignant, chronic intractable pain as documented in the medical history
  12. Subjects who are medically stable and able to undergo surgery for implantation of the Prometra® II Infusion System
  13. Subject must have completed a psychological evaluation within 6 months prior to Screening
  14. Subject must complete an intrathecal trial resulting in candidacy for pump implantation during Screening

Exclusion Criteria:

A potential subject who has any contraindications listed in the Prometra® II labeling or any contraindications of intrathecal agents employed in the United States within the PACC, will be excluded. All subjects meeting any of the following criteria will also be excluded from this study:

  1. Subjects currently have a spinal cord stimulator implanted for pain
  2. Subjects previously had a spinal cord stimulator implanted for pain
  3. Subjects who have psychological or other health conditions, financial, and/or legal concerns (within 3 months prior to Screening) that would interfere with the subject's ability to fulfill the requirements of the protocol as per the investigator's opinion
  4. Subjects who have a history of alcohol abuse or illicit drug use within 2 years of screening
  5. Subjects who have an active malignancy or has been diagnosed with cancer and has not been in remission for at least 1 year prior to Screening
  6. Subjects who are female and who are pregnant, nursing or planning a pregnancy during the study or females of childbearing potential who are unable or unwilling to use a form of contraception during the study.
  7. Subjects who plan to enroll or is currently enrolled in another investigational drug or investigational medical device study or has participated in an investigational drug or medical device study within 30 days prior to Screening
  8. Subject has any condition or situation which, in the investigator's opinion, puts the patient at significant risk, could confound the study results, or may interfere significantly with the subject's participation in the study

    At the Baseline Visit or prior to Randomization, a subject will be excluded from continued participation if the subject has:

  9. Subjects that have a mean of the reported 12 hour "average" NPRS responses of < 6 on an eleven-point scale (0 to10) rated over the 5 days prior to the Baseline Visit (as recorded in the electronic Study Diary) in the absence of intolerable side effects as documented in the medical history
  10. Subjects with a negative urine test for opioids at Baseline
  11. Subjects with a positive Pregnancy test, if applicable
  12. Subjects that failed the intrathecal trial during Screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04096391


Contacts
Layout table for location contacts
Contact: Jannelle V Molina, BA (844) 527-7369 crc@erc.care
Contact: Jason E Pope, MD (844) 527-7369 popeje@me.com

Locations
Layout table for location information
United States, California
Evolve Restorative Center Recruiting
Santa Rosa, California, United States, 95403
Contact: Jannelle V Molina, BA    844-527-7369    crc@erc.care   
Principal Investigator: Jason E Pope, MD         
Sponsors and Collaborators
Evolve Restorative Center
Flowonix Medical
Celéri Health
Advanced Infusion Solutions
Investigators
Layout table for investigator information
Principal Investigator: Jason E Pope, MD Evolve Restorative Center
Publications:

Layout table for additonal information
Responsible Party: Evolve Restorative Center
ClinicalTrials.gov Identifier: NCT04096391    
Other Study ID Numbers: Prosper-001
First Posted: September 19, 2019    Key Record Dates
Last Update Posted: June 9, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Evolve Restorative Center:
Truncal Pain
Lower Extremity Limb Pain
Refractory Pain
Additional relevant MeSH terms:
Layout table for MeSH terms
Chronic Pain
Pain, Intractable
Pain
Neurologic Manifestations
Signs and Symptoms
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs